Skopos Labs, Inc. Nuvalent, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 2 shares of NUVL stock, worth $196. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$196
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
230Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.77 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$517 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$297 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$176 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.22B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...